Benhamou, Pierre Yves http://orcid.org/0000-0003-4378-0468
,
Huneker, Erik
Franc, Sylvia
Doron, Maeva
Charpentier, Guillaume
Funding for this research was provided by:
AVIESAN
CERITD
Article History
Received: 9 January 2018
Accepted: 23 February 2018
First Online: 9 March 2018
Compliance with ethical standards
:
: The authors declare the following disclosures: Erik Huneker is CEO of Diabeloop S.A. Guillaume Charpentier is chairman of Diabeloop S.A. Erik Huneker, Guillaume Charpentier and Sylvia Franc are shareholders in Diabeloop S.A. The other authors (Pierre Y. Benhamou, Maeva Doron, and all other members of the Diabeloop consortium) declare no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
: Informed consent was obtained from all patients prior to their inclusion in the study.